Episode notes
This week on the podcast, we have a conversation with Tim Tinnel, executive vice president/chief operating officer of Intelliguard, talking about – among other things – the looming Drug Supply Chain Security Act (DSCSA) deadline, and Jorge Jorge Santos da Silva, founder and CEO of MoonLake Immunotherapeutics, about its Nanobody programme.
Interview times:
01:42 MoonLake Immunotherapeutics
25:24 Intelliguard
MoonLake Immunotherapeutics
Later this year, MoonLake Immunotherapeutics will be announcing its hotly anticipated phase 3 results for its Nanobody sonelokimab for the skin condition hidradenitis suppurativa. The company is looking to sonelokimab t ...
Keywords
biotechbiotechnologyIntelliguardNanobodyMoonLake ImmunotherapeuticsDSCSAhidradenitis suppurativa